Tumour necrosis factor α (TNF-α), interleukin-6 (IL-6) and their soluble receptors (sTNF-α-Rp55 and slL-6R) serum levels in systemic lupus erythematodes

Mediators of Inflammation

Volumn 5, Issue 6, 1996, Pages 435-441

  Robak, E ^a   Sysa Jedrzejowska A ^a   Wozniacka A ^a   Waszczykowska, E ^a   Robak, T ^a   Stepien H ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Disease activity; Interleukin 6; Soluble interleukin 6 receptor; Soluble tumour necrosis factor receptor p55; Systemic lupus erythematodes; Tumour necrosis factor

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030476619     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/S0962935196000609     Document Type: Article

References (38)

1. Swaak AJG, Nossent JC, Smeenk RJT. Systemic lupus erythematosus. Int J Clin Res 1992; 22: 190–195.
2. Horwitz DA, Jacob CO. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol 1994; 16: 181–200.
3. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 1992; 63: 10–12.
4. Handwerger BS, Rus V, da Silva L, Via CS. The role of cytokines in the immunopathogenesis of lupus. Springer Semin Immunopathol 1994; 16: 153–180.
5. Gordon C, Emery P. Cytokines and acute phase response in SLE. Lupus 1993; 2: 345–347.
6. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 1992; 63: 10–12.
7. Bazzoni F, Beutler В. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717–1725.
8. Kishimoto T, Taga T, Akira S. Catokine signal transduction. Cell 1994; 76: 253–262.
9. Heaney ML, Golde DW. Soluble cytokine receptors. Blood 1996; 87: 847–857.
10. Maury CPJ, Teppo Α-M. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 146–150.
11. Meijer C, Huysen U, Smeenk RTJ, Swaak AJG. Profiles of cytokines (TNF-α and IL-6) and acute phase proteins (CRP and α 1 AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993; 2: 359–365.
12. Al-Janadi M, Al-Balla S, Al Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic diseases. J Clin Immunol 1993; 13: 58–67.
13. Linker-Israeli M, Deans RJ, Wallace DJ, Prhn J, Oxzeri-Chen T, Klinberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. J Immunol 1991; 147: 117–123.
14. Spronk PE, ter Borg EJ, Limburg PC, Kallenberg CGM. Plasma concentration of IL-6 in systemic lupus erythematosus: an indicator of disease activity. Clin Exp Immunol 1992; 90: 106–110.
15. Gabay C, Roux-Lombard P, de Moerloose P, Dayer JD, Vischer T, Guerne PA. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993; 20: 815–821.
16. Metsariune KP, Nordstrom CDE, Konttinen YT, Teppo AM, Fyhrquist FY. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis and systemic lupus erythematosus. Rheumatol Int 1992; 12: 93-96.
17. Ruiz AD, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995; 54: 1–8.
18. Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Vallain D, Kustai Y. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991; 51: 5602–5607.
19. Samsonov MY, Tilz GP, Egorova O, Reitnegger G, Balabanova RM, Vassomov EL, Nassonova VA, Wachter H, Fuchs D. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1996; 4: 29–32.
20. Aderka D, Wysenbeck A, Engellman H, Cope AP, Brennan FM, Molad FY, Hornick V, Levo Y, Maini RN, Feldmann M, Wallach D. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1111–1120.
21. Heilig B, Fiehn C;, Brockhaus M, Gallati M, Pezzutto A, Hunstein W. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993; 13: 321–328.
22. Yasuhawa K, Futatsugi K, Saito T, Valvata H, Narazolin M, Suzuki H, Taga T, Hishimoto T. Association of recombinant soluble IL-6-signal transducer, gp 130, with a complex of IL-6 and soluble IL-6 receptor and establishment of an ELISA for soluble gp 130. Immunol Lett 1992; 31: 123–130.
23. Müllberg J, Schooltink H, Stoyan T, Gunther M, Greave L, Buse G, Machiewicz A, Heinrich PC, Rose-John S. The human soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993; 23: 473.
24. Müllberg J, Oberthür W, Lottspeich F, Mehl T, Dittrich Τ, Graeve L, Heinrich PL, Rose-John S. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 1934; 152: 4958–4968.
25. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.
26. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthr Rheum 1989; 32: 1107–1118.
27. Malave J, Searles RP, Montano J, Williams RC Jr. Production of tumor necrosis factor/cachectin by peripheral blood mononuclear cells in patients with systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1989; 89: 355–361.
28. Maini RN, Elliott MJ, Charles PJ, Feldmann H, Immunological interventions reveals reciprocal roles for tumor necrosis factor-α and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus. Springer Semin Immunol 1994; 16: 327–336.
29. Kitani AM, Hara M, Hirose M, Harigami M, Suzuki K, Kawakami M, Kawaguchi Y, Hidaka T, Kawagoe M, Nakamuri T. Autostimulatory effects of IL-6 on excessive В cell differentiation in patients with systemic lupus erythematosus; analysis of IL-6R expression. Clin Exp Immunol 1992; 75-83.
30. Nagafuchi H, Suzuki N, Mizushima Y, Sakane T. Constitutive expression of IL-6 receptors and their role in the excessive В cell function in patients with systemic lupus erythematosus. J Immunol 1993; 151: 6525–6534.
31. Tracey JK. Tnf and Mae West or: death from too much of a good thing. N Engl J Med 1995; 345: 75–76.
32. Ter Borg EJ, Horst G, Limburg PC, Kallenberg CGM. Changes in plasma Ievels of interleukin 2 receptors in relation to disease exacerbations and levels of anti-ds DNA and complement in systemic lupus erythematosus. Clin Exp Immunol 1990; 82: 21–26.
33. Engelberts J, Moeller A, Schoen GJM, van der Linde CJ, Bunrman WA. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 1991; 10: 69–76.
34. Van Zee KJ, Kohno T, Fischer, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845.
35. Aderka D, Engellmann H, Maor Y, Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323–239.
36. Honda M. Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, Osugi Y, Tokunaga T, Hishimoto Τ. Human soluble IL-6 receptor: its detection and enhanced released by HIV infection. J Immunol 1992; 146: 2175–2189.
37. Kishimoto T, Taga T, Akira S. Catokine signal transduction. Cell 1994; 76: 253–262.
38. Gailard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M., Marwo N, Taga T, Kishimoto T, Klein B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammapathy. Eur J Immunol 1993; 23: 820–824.